To evaluate the effect of Dxm on the inflammatory process in the early phase of CLD (postnatal age 10-16 days), tracheal aspirate fluid (TAF) from 16 preterm infants (BW 891 ± 46 gms, GA 27.1 ± 0.4 wks, mean ± SEM) was assessed for chemotactic activity and indicators of inflammation. After Dxm therapy chemotactic response of blood neutrophils exposed to TAF decreased (migratory distance before Dxm 150 ±10um, after Dxm 91 ±11μm, p<0.001); additionally the influx of TAF-neutrophils was reduced (before Dxm 492 ±165 cells/μl effluent, after Dxm 77 ± 22, p<0.01) Elastase-alpha-1-Proteinaseinhibitor(a-1-PI)- complex decreased after treatment (before Dxm 534 ± 154, after Dxm 65 ±18 ng /ml, p<0.01). Before Dxm, free elastolytic activity was only present in one infant, 15/16 had a protective activity of a-1-PI. Concentrations of albumine were lower after Dxm(before Dxm 29 ±6, after Dxm 7 ±1 mg/dl, p<0.001), Interleukin-1 similary decreased. The reported effects could not be observed in untreated control infants (n=8). We conclude that Dxm reduces the pulmonary inflammatory reaction of preterm infants during the early phase of CLD
Supported by a grant of Deutsche ForachungegemeinBchaft (Sp 239/3-1).